Chronic Kidney Disease in Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  McFarlane, Philip ^a   Gilbert, Richard E ^a   MacCallum, Lori ^a   Senior, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RENIN INHIBITOR;

ACUTE KIDNEY FAILURE; ALBUMIN TO CREATININE RATIO; ALBUMIN URINE LEVEL; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMATURIA; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PREGNANCY DIABETES MELLITUS; PROTEINURIA; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; URINALYSIS; URINARY EXCRETION; URINE LEVEL; CANADA; DIABETIC NEPHROPATHIES; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC;

CANADA; DIABETIC NEPHROPATHIES; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84876015571     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.037     Document Type: Article

References (90)

1. Warram J.H., Gearin G., Laffel L., et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996, 7:930-937.
2. Reenders K., de Nobel E., van den Hoogen H.J., et al. Diabetes and its long-term complications in general practice: a survey in a well-defined population. Fam Pract 1993, 10:169-172.
3. Weir M.R. Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int 2004, 66:S38-S39.
4. Canadian Institute for Health Information Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2000 to 2009 2011, Canada, Ottawa, ON.
5. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
6. Bell C.M., Chapman R.H., Stone P.W., et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decision Making 2001, 21:288-294.
7. Mazzucco G., Bertani T., Fortunato M., et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002, 39:713-720.
8. Gambara V., Mecca G., Remuzzi G., et al. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993, 3:1458-1466.
9. Mathiesen E.R., Ronn B., Storm B., et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995, 12:482-487.
10. Lemley K.V., Abdullah I., Myers B.D., et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000, 58:1228-1237. Published erratum appears in Kidney Int. 2000;58:2257.
11. Gall M.A., Nielsen F.S., Smidt U.M., et al. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993, 36:1071-1078.
12. Jacobsen P., Rossing K., Tarnow L., et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999, 71:S101-S105.
13. Hasslacher C., Ritz E., Wahl P., et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989, 4:859-863.
14. Biesenbach G., Bodlaj G., Pieringer H., et al. Clinical versus histological diagnosis of diabetic nephropathy: is renal biopsy required in type 2 diabetic patients with renal disease?. QJM 2011, 104:771-774.
15. Middleton R.J., Foley R.N., Hegarty J., et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006, 21:88-92.
16. Ruggenenti P., Gambara V., Perna A., et al. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998, 9:2336-2343.
17. VenkataRaman T.V., Knickerbocker F., Sheldon C.V. Unusual causes of renal failure in diabetics: two case studies. J Okla State Med Assoc 1990, 83:164-168.
18. Anonymous Clinical path conference. Unusual renal complications in diabetes mellitus. Minn Med 1967, 50:387-393.
19. Amoah E., Glickman J.L., Malchoff C.D., et al. Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol 1988, 8:204-211.
20. El-Asrar A.M., Al-Rubeaan K.A., Al-Amro S.A., et al. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 2001, 24:1-11.
21. Ballard D.J., Humphrey L.L., Melton L.J., et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988, 37:405-412.
22. Winaver J., Teredesai P., Feldman H.A., et al. Diabetic nephropathy as the mode of presentation of diabetes mellitus. Metab Clin Exp 1979, 28:1023-1030.
23. Ahn C.W., Song Y.D., Kim J.H., et al. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Med J 1999, 40:40-45.
24. Kouri T.T., Viikari J.S., Mattila K.S., et al. Microalbuminuria. Invalidity of simple concentration-based screening tests for early nephropathy due to urinary volumes of diabetic patients. Diabetes Care 1991, 14:591-593.
25. Rodby R.A., Rohde R.D., Sharon Z., et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995, 26:904-909.
26. Chaiken R.L., Khawaja R., Bard M., et al. Utility of untimed urinary albumin measurements in assessing albuminuria in black NIDDM subjects. Diabetes Care 1997, 20:709-713.
27. Bakker A.J. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999, 22:307-313.
28. Huttunen N.P., Kaar M., Puukka R., et al. Exercise-induced proteinuria in children and adolescents with type 1 (insulin dependent) diabetes. Diabetologia 1981, 21:495-497.
29. Solling J., Solling K., Mogensen C.E. Patterns of proteinuria and circulating immune complexes in febrile patients. Acta Med Scand 1982, 212:167-169.
30. Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999, 245:111-126.
31. Wiseman M., Viberti G., Mackintosh D., et al. Glycaemia, arterial pressure and micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1984, 26:401-405.
32. Ravid M., Savin H., Lang R., et al. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 1992, 152:1225-1229.
33. Gault M.H., Longerich L.L., Harnett J.D., et al. Predicting glomerular function from adjusted serum creatinine. Nephron 1992, 62:249-256.
34. Bending J.J., Keen H., Viberti G.C. Creatinine is a poor marker of renal failure. Diabet Med 1985, 2:65-66.
35. Shemesh O., Golbetz H., Kriss J.P., et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985, 28:830-838.
36. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
37. Poggio E.D., Wang X., Greene T., et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005, 16:459-466.
38. Wang P.H., Lau J., Chalmers T.C. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993, 341:1306-1309.
39. Anonymous Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995, 47:1703-1720.
40. Anonymous Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
41. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Eng J Med 2000, 342:381-389.
42. Shichiri M., Kishikawa H., Ohkubo Y., et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl 2):B21-B29.
43. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
44. Schrier R.W., Estacio R.O., Mehler P.S., et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007, 3:428-438.
45. de Galan B.E., Perkovic V., Ninomiya T., et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883-892.
46. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
47. Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787-1792.
48. Bilous R., Chaturvedi N., Sjolie A.K., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151:11-20. W13-W14.
49. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
50. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
51. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
52. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353:617-622.
53. Levey A.S., Coresh J. Chronic kidney disease. Lancet 2012, 379:165-180.
54. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
55. Maki D.D., Ma J.Z., Louis T.A., et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995, 155:1073-1080.
56. Kasiske B.L., Kalil R.S., Ma J.Z., et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993, 118:129-138.
57. Barnett A.H., Bain S.C., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
58. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
59. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
60. Andersen S., Tarnow L., Rossing P., et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601-606.
61. Strippoli G.F., Craig M.C., Schena F.P., et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006, 17:S153-S155.
62. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001, 345:851-860.
63. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
64. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
65. Laffel L.M., McGill J.B., Gans D.J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497-504.
66. Mathiesen E.R., Hommel E., Giese J., et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991, 303:81-87.
67. Jerums G., Allen T.J., Campbell D.J., et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001, 37:890-899.
68. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001, 134:370-379.
69. Ravid M., Savin H., Jutrin I., et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577-581.
70. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
71. Maschio G., Alberti D., Locatelli F., et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999, 33(suppl 1):S16-S20. discussion S41-S43.
72. Shoda J., Kanno Y., Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 2006, 45:193-198.
73. Igarashi M., Hirata A., Kadomoto Y., et al. Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocr J 2006, 53:493-501.
74. Jacobsen P., Parving H.H. Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney Int 2004, 66:S108-S110.
75. Burgess E., Muirhead N., Rene de Cotret P., et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009, 20:893-900.
76. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
77. Parving H.H., Persson F., Lewis J.B., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
78. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
79. Bakris G.L., Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
80. Reams G.P., Bauer J.H., Gaddy P. Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-aldosterone system. Hypertension 1986, 8:290-297.
81. Franklin S.S., Smith R.D. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985, 79:14-23.
82. Miyamori I., Yasuhara S., Takeda Y., et al. Effects of converting enzyme inhibition on split renal function in renovascular hypertension. Hypertension 1986, 8:415-421.
83. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004, 351:585-592.
84. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
85. Levin A, Mendelssohn D. Care and referral of adult patients with reduced kidney function: position paper from the Canadian Society of Nephrology. 2006.
86. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
87. Mathiesen E.R., Hommel E., Hansen H.P., et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999, 319:24-25.
88. Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. MicroAlbuminuria Reduction With VALsartan Study Investigators. Circulation 2002, 106:672-678.
89. Tobe S.W., Clase C.M., Gao P., et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011, 123:1098-1107.
90. Parving H., Brenner B.M., McMurray J.J.V., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.